Gene therapies for rare diseases are under threat. Scientists hope to save them
By Heidi Ledford,
Nature
| 10. 06. 2023
It was one of gene therapy’s greatest successes — and greatest disappointments.
Strimvelis is a potent treatment for a devastating genetic disorder of the immune system and one of the first gene therapies to be approved in Europe. But in 2022, the company that sold it announced that it could no longer afford to do so: Strimvelis was highly effective at treating disease, but not at turning a profit.
Now it is getting a second chance. The Italian charity Telethon Foundation in Milan has announced that it will produce Strimvelis itself. “We are making a paradigm shift,” said Francesca Pasinelli, general manager of the Telethon Foundation, in a 12 September statement announcing the decision. “We are the first non-profit organization to take on the commercialization of a gene therapy.”
The charity’s unprecedented scheme offers hope to scientists who have spent decades developing gene therapies for rare disorders, only to find that the standard way of getting those treatments to people in need — licensing them to for-profit companies — is unavailable. Other unorthodox ways to keep these efforts going...
Related Articles
By Ian Sample, The Guardian | 07.04.2024
Biological models of human embryos that can develop heartbeats, spinal cords and other distinctive features will be governed by a code of practice in Britain to ensure that researchers work on them responsibly.
Made from stem cells, they mimic, to...
By Kevin Davies, Genetic Engineering & Biotechnology News | 06.27.2024
Physician-scientist Matthew Porteus, MD, PhD, has been a mainstay in the genome editing field for more than two decades. He trained at Stanford University Medical School before completing his residency and hematology/oncology fellowship at Boston Children’s Hospital/Dana Farber Cancer Institute...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...
By Robert F. Service, Science | 07.04.2024
Image by Ed Uthman from Flickr
Last year, the U.S. Food and Drug Administration (FDA) approved two gene therapy procedures that can treat and, in some cases essentially cure sickle cell disease, a genetic blood disorder that causes pain and...